Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2000
03/22/2000EP0986384A1 Inhibitors of protein isoprenyl transferases
03/22/2000EP0986382A1 Raf kinase inhibitors
03/22/2000EP0986379A1 Use of substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity to prevent or reduce ischemic injury
03/22/2000EP0986376A1 COMPOSITIONS FOR TREATING AND PREVENTING ARTERIAL THROMBOSIS AND USE OF A FACTOR Xa INHIBITOR ON ITS OWN AND/OR COMBINED WITH A PLATELET ANTIAGGREGATING AGENT
03/22/2000EP0986314A1 Probiotic lactic acid bacterium to treat bacterial infections associated with sids
03/22/2000EP0986302A1 A method of treating cancer
03/22/2000EP0790997B1 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
03/22/2000EP0675713B1 Use of prodelphinidines for treating arthrosis
03/22/2000CN1248291A Phosphodiesterase 8A
03/22/2000CN1248263A Process for preparing carboxamido-4-azasteroids
03/22/2000CN1248254A Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for treatment of neurodegenerative and CNS-trauma related conditions
03/22/2000CN1248253A Tricyclic compounds useful for inhibition of farnesyl protein transferase
03/22/2000CN1248249A 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
03/22/2000CN1248248A Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists
03/22/2000CN1248246A 4-aminoethoxyindazole derivatives
03/22/2000CN1248162A Topical pharmaceutical composition comprising cholinergic agent or calcium channel blocker
03/22/2000CN1050601C Novel aminoalkyl benzothiazolinone, its prepn. and medical composition containing the compound
03/21/2000US6040475 Intermediate compounds for making metabolites of lycopene
03/21/2000US6040447 Reacting a halogenated amino pyrimidine compound with acid anhydride or acid halide to form an intermediate, transforming the 6-halo group of the intermediate to an amine by displacement with ammonia, cyclizing with a base
03/21/2000US6040431 Single chain analogs of the TGF-β superfamily (morphons)
03/21/2000US6040346 Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs
03/21/2000US6040344 Crystalline r,r-formoterol l-(+)-tartrate.
03/21/2000US6040329 Substituted indazole analogs
03/21/2000US6040328 Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use
03/21/2000US6040327 Benzimidazole, benzoxazole and benzothiazole compounds
03/21/2000US6040326 3-deoxyglucosone production inhibitor
03/21/2000US6040323 Phosphatase inhibitors and methods of use thereof
03/21/2000US6040321 Enzyme inhibitor treating cancer, inflammation and arthritis, neurodegenerative diseases such as alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases
03/21/2000US6040320 Antiinflammatory agent for treating diseases associated with overproduction of inflammatory cytokines, such as rheumatoid arthritis, inflammatory bowel disease, septic shock, osteoporosis, and osteoarthritis
03/21/2000US6040319 cyclization; synthesis of cyclooxygenase-2 (COX) inhibitors such as etoricoxib
03/21/2000US6040317 Sulfonamide fibrinogen receptor antagonists
03/21/2000US6040314 Bicyclic isothiourea derivatives useful in therapy
03/21/2000US6040312 Formulations and methods of reducing toxicity of antineoplastic agents
03/21/2000US6040310 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists
03/21/2000US6040304 Formulations and methods of reducing toxicity of antineoplastic agents
03/21/2000US6040303 7-phenyl-1, 4-diazepane compounds, process for their preparation, and pharmaceutical compositions containing them
03/21/2000US6040294 The compounds have either a sulfhydryl moiety or are reducible disulfides; reducing the side effect of cancer drug
03/21/2000US6040289 Active drug treating obesity
03/21/2000US6039974 Drugs of multilayer tablets
03/21/2000US6039683 Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
03/21/2000CA2146097C 1h-indole-3-glyoxylamide spla2 inhibitors
03/21/2000CA2027773C Treatment of shock by cyclodextrins and their derivatives
03/21/2000CA2000468C Piperidinyl benzimidazoles
03/17/2000CA2282234A1 Antitumor activity strengthening method of crude drugs, composition containing crude drug strengthening antitumor activity, evaluating method of antitumor effectiveness by crude drug treatment, and evaluating method of antitumor effectiveness of crude drug
03/17/2000CA2282112A1 Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
03/16/2000WO2000014235A1 Kunitz domain polypeptide zkun6
03/16/2000WO2000014222A2 GABAB RECEPTOR SUBTYPES GABAB-R1c AND GABAB-R2 AND HETERODIMERS THEREOF
03/16/2000WO2000014110A1 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
03/16/2000WO2000014106A1 Novel bag proteins and nucleic acid molecules encoding them
03/16/2000WO2000014095A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
03/16/2000WO2000014089A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000WO2000014086A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000WO2000014083A1 SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
03/16/2000WO2000014065A1 Kappa agonist compounds and pharmaceutical formulations thereof
03/16/2000WO2000014063A1 Therapeutic compounds and methods
03/16/2000WO2000014054A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000WO2000013709A2 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
03/16/2000WO2000013707A1 Preventives/remedies for multiple organ failure
03/16/2000WO2000013703A2 Methods of treating hypertension and compositions for use therein
03/16/2000WO2000013702A2 Use of an angiogenic factor for the treatment of microvascular angiopathies
03/16/2000WO2000013700A1 Method of using fetuin to induce apoptosis in cancer cells
03/16/2000WO2000013671A1 Immediate release tablet
03/16/2000WO2000013667A1 Lipstatin derivative-soluble fiber tablets
03/16/2000WO2000013660A1 Lipid extract of the skeletonema algae
03/16/2000WO2000002582A3 Treatment of celiac disease with interleukin-15 antagonists
03/16/2000WO1999067363A9 Ependymal neural stem cells and method for their isolation
03/16/2000WO1999067252A3 Epothilone derivatives and their synthesis and use
03/16/2000WO1999065910A9 Fused azepinone cyclin dependent kinase inhibitors
03/16/2000WO1999064047A9 Novel antiviral compounds
03/16/2000WO1999063932A9 Multibinding agents that modulate the 5-ht transporter
03/16/2000WO1999063929A9 Multibinding inhibitors of microsomal triglyceride transferase protein
03/16/2000WO1999062939A3 Glycoproteins having lipid mobilising properties and therapeutic applications thereof
03/16/2000WO1999059499A3 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
03/16/2000WO1999050403A9 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
03/16/2000WO1999012561A9 FRACTURE HEALING USING PTHrP ANALOGS
03/16/2000CA2345050A1 Method of using fetuin to induce apoptosis in cancer cells
03/16/2000CA2343536A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2343027A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
03/16/2000CA2342994A1 Kappa agonist compounds and pharmaceutical formulations thereof
03/16/2000CA2342898A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000CA2342882A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2342858A1 Method of screening compounds useful in the treatment of a desease caused by or exacerbated by mpv
03/16/2000CA2342796A1 Preventives/remedies for multiple organ failure
03/16/2000CA2342625A1 Lipstatin derivative-soluble fiber tablets
03/16/2000CA2342349A1 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
03/16/2000CA2342027A1 Novel bag proteins and nucleic acid molecules encoding them
03/16/2000CA2341325A1 Method of stimulating prosaposin receptor activity
03/16/2000CA2341259A1 Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
03/15/2000EP0985149A1 Methods for evaluating tissue morphogenesis and activity
03/15/2000EP0985040A1 Preparation of glycosylated tumor necrosis factor
03/15/2000EP0985038A1 Sodium channel receptor
03/15/2000EP0985037A1 Human multiple endocrine neoplasia type 1 protein
03/15/2000EP0985036A1 Zinc ring protein
03/15/2000EP0985035A2 Dna methyltransferase genomic sequences and antisense oligonucleotides
03/15/2000EP0985030A2 New human ribonuclease
03/15/2000EP0984987A2 A soluble laminin receptor precursor and methods to ihnibit its interactions
03/15/2000EP0984986A2 Human type 3 ryanodine receptor protein and dna molecules coding therefor
03/15/2000EP0984983A2 Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and a kinase domain
03/15/2000EP0984981A1 Anti-inflammatory tyrosine derivatives
03/15/2000EP0984980A1 20-ARALKYL-5$g(a)-PREGNANE DERIVATIVES
1 ... 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 ... 1564